When everyone else is panicking, it’s time to swoop in and pick up some undervalued assets.

Easy enough in theory, but in practice it takes some work to determine what’s an undervalued asset and what’s the contemporary equivalent of Confederate money. The stock of a randomly selected social gaming company, whose products are ultimately of limited utility, might likely fall in the latter category. The stock of a biotechnology company that provides, or might one day provide, vital benefits to humanity is a different investment altogether. With the NASDAQ Biotechnology Index now off 18.5% from its latest zenith, some of the stocks whose price movements have contributed to that decline are ripe for the shrewd and opportunistic investor.

The NASDAQ Biotechnology Index (Nasdaq:NBI) tracks the movements of the stocks of 121 companies, each of which has a market capitalization of at least $200 million (among other criteria.) However, unlike the Dow Jones Industrial Average or other principal indices, the NASDAQ biotech index is weighted. Its top nine components make up most of the index’s value.

Musical Chairs

In the last few weeks, the biotech industry has been one of the most dynamic in the market, undergoing so many asset sales and takeover attempts that you need a scorecard and several pencils to keep track of the movements. Montreal’s Valeant Pharmaceuticals International (NYSE:VRX) made a hostile bid for Irvine, Calif.'s Allergan Inc. (NYSE:AGN). New York’s Pfizer Inc. (NYSE:PFE) made a similar overture to London-based AstraZeneca plc (NYSE:AZN). Meanwhile, Basel, Switzerland-based Novartis International AG (NYSE:NVS) swapped its vaccine operations (along with billions in cash) for Brentford, England-based GlaxoSmithKline plc’s (NYSE:GSK) cancer business. Once everything settles and we have some stability, to the extent that the market is ever stable, expect fewer players wielding greater influence than ever before in this growing sector.

One company that’s emerged to possibly thwart a takeover is Thousand Oaks, Calif.-based Amgen Inc. (Nasdaq:AMGN), a maker of some serious pharmaceuticals that you should consider yourself fortunate to never receive a prescription for. These include Enbrel, a rheumatoid arthritis drug that runs about $2,700 per month; and Neulasta, a white blood cell stimulant for leukemia patients that makes Enbrel look like a bargain.

Amgen stock has remained somewhat consistent for the last three quarters, and at least one analyst thinks the company could best Pfizer’s offer for AstraZeneca. That would be a fitting next stage to Amgen’s and AstraZeneca’s two-year-old agreement to jointly develop drugs that fight everything from colitis to lupus.

Amgen Undervalued?

But is Amgen stock an undervalued asset? The company is the second-largest component of the NASDAQ biotech index, comprising approximately 8% of its value. The stock trades at about 17 times earnings, which is not only low for its industry but low for Amgen’s ability to earn. Profit margins were 27% last year, this in a business where large research and development expenses are part of the game. Dividend payouts are generous, making the company’s only true negative metric being its inability to meet Wall Street forecasts. For a certain type of investor, there’s nothing remotely negative about that.

Foster City, Calif.-based Gilead Sciences Inc. (Nasdaq:GILD) is the NASDAQ biotech index’s third-largest component, and its second-largest with fundamentals that bear at least a superficial similarity to Amgen’s. Gilead initially gained fame for its HIV/AIDS drugs, and expanded into hepatitis C therapy in 2011. The company did the latter by acquisition, with unmistakable results.

Last month, the newly fortified Gilead brought a phenomenally effective hepatitis C drug to market, one so groundbreaking that the U.S. Food and Drug Administration fast-tracked it. The drug, Sovaldi, treats patients over a three-month period, which is considerably shorter than the industry standard for hepatitis C regimens. Three months’ worth of Sovaldi costs $84,000. Some insurers balk at the price tag, but Gilead’s margins on Sovaldi are merely high, not extortionate. They contribute to an overall company profit margin of around 27%, which is actually down from 33% a couple of years ago but still the envy of most every established company on the exchange. Down off its late-February zenith, Gilead currently trades in the high 70s, allowing considerable room to reach the consensus one-year target estimate that’s knocking on the door of three digits, which would be a all-time high for the company.

The Bottom Line

Nothing offers guaranteed appreciation. But at least you can invest in something whose indicators appear to indicate an eventual gain. With the recent pullback in shares, a few of the NASDAQ biotech index's components appear to be capable of making today’s buyers very happy.

Related Articles
  1. Chart Advisor

    Biotechnology Stocks To Keep on the Radar

    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  2. Stock Analysis

    The 5 Best Alternatives to Zillow & Trulia

    Understand the online real estate industry and how Zillow and Trulia are industry leaders. Learn about alternatives to Zillow and Trulia.
  3. Stock Analysis

    How UPS Plans to Benefit from Its Coyote Acquisition

    Understand the business models of UPS and Coyote Logistics. Learn about the top four ways in which UPS will benefit from the acquisition of Coyote Logistics.
  4. Stock Analysis

    The 5 Best Buy-and-Hold Energy Stocks

    Understand why energy companies' stock are volatile when oil prices are volatile. Learn about the top five energy companies to buy and hold.
  5. Stock Analysis

    How Does Oscar Work and Make Money?

    Learn how startup Oscar is taking on the health insurance giants by offering customers free doctor's visits, generic drugs and 24-hour phone access to doctors.
  6. Stock Analysis

    Twitter Vs. Facebook Vs. Instagram: Who Is the Target Audience?

    Learn why Facebook, Twitter and Instagram each appeal to different target markets of the 1 billion users of social networks worldwide.
  7. Chart Advisor

    ChartAdvisor for October 2 2015

    Weekly technical summary of the major U.S. indexes.
  8. Stock Analysis

    The Biggest Risks of Investing in Amazon Stock

    Find out which risks are most important to Amazon's shareholders. Learn which operational risks impact share prices and which financial risks affect investors.
  9. Technical Indicators

    Why MACD Divergence Is an Unreliable Signal

    MACD divergence is a popular method for predicting reversals, but unfortunately it isn't very accurate. Learn the weaknesses of indicator divergence.
  10. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  1. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>
  2. What factors make the drug sector good for value investing?

    The drugs sector is a good choice for value investing because it always has demand and a competitive moat. This simplifies ... Read Full Answer >>
  3. What annual return could an investor expect on average from the drug sector?

    The drugs sector consists of a diverse group of companies of different sizes in terms of market cap, revenues, profitability ... Read Full Answer >>
  4. What are the primary factors that drive share prices in the drugs sector?

    The primary factors that drive share prices in the drugs sector are mergers and acquisitions activity, spending on health ... Read Full Answer >>
  5. How does the profit margin compare for a generic drug versus a brand name drug?

    Profit margins are higher for generic drugs compared to brand-name drugs. However, total profits on brand-name drugs are ... Read Full Answer >>
  6. What level of return on equity is average for a company in the drugs sector?

    The drugs sector provides a variety of investing opportunities ranging from major drug manufacturing companies to generic ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!